1. Home
  2. Detail

@ix_44j: عيني الجبور 😂 . . #صلاح_الدين_تكريت #اغاني_عراقيه #اغاني_مسرعه💥 #تصاميم_فيديوهات🎵🎤🎬 #جوبي_عراقي #دبكات_طرب #لايككككككككككككككك

حـُـر🇮🇶✨
حـُـر🇮🇶✨
Open In TikTok:
Region: IQ
Saturday 12 April 2025 15:29:47 GMT
17299
424
8
73

Music

Download

No Watermark .mp4 (0.7MB) No Watermark(HD) .mp4 (1.06MB) Watermark .mp4 (1.18MB) Music .mp3

Comments

to.0713
بطه🦆. :
فديتنه🗿😂..
2025-05-20 16:26:24
1
y.t1b1
كـــريـسـ³¹³ :
😂
2025-04-13 18:13:54
2
exxpq8
مغلق. :
😂
2025-04-12 18:54:56
2
m_gkjj
تيتي :
😂
2025-09-02 20:28:09
0
To see more videos from user @ix_44j, please go to the Tikwm homepage.

Other Videos

⭐️ Let’s talk about the EMBER-3 trial which was presented today and published in @nejm. Imlunestrant is a novel, next-generation, brain-penetrant (!!), oral selective estrogen receptor degrader (SERD) and pure estrogen receptor antagonist. It delivers continuous estrogen receptor inhibition even in ESR1 mutated breast cancer (where there is a mutation in the gene encoding the estrogen receptor alpha). 🔸In the EMBER-3 trial, patients with HR+/HER2- metastatic breast cancer that had developed a recurrence or progression during or after AI therapy (65% had also received. CDK 4/6 inhibitor). Patients received either standard endocrine monotherapy (330 patients) (fulvestrant or exemestane), imlunestrant alone (331 patients), or imlunestrant + abemaciclib (Verzenio, a CDK 4/6 inhibitor) (213 patients). 🔸Imlunestrant improved progression free survival (PFS) (time without progression or death) compared to standard endocrine therapy: 5.5 mo vs 3.8 months in patients with ESR1 mutations. There was no difference in patients who did not have ESR1 mutations. 🔸 Imlunestrant+abemaciclib vs imlunestrant alone improved PFS in all patients: 9.4 mo vs 5.5 months (43% reduction in risk of progression or death). The benefit was seen regardless of ESR1 mutation status. 🙄The common side effects of imlunestrant include: fatigue 😴, diarrhea 💩, nausea 🤢 and joint pain 🦴. (Side effects were increased when fulvestrant combined with abemaciclib). Preliminary analysis suggests that imlunestrant therapy involves ⬇️ risks of bradycardia (slow heart rate), high cholesterol, and visual 👀 disturbances than other new SERDs. 🚨 Bottom line: Imlunestrant, as monotherapy or in combination with abemaciclib, provides an oral targeted-therapy option after progression during endocrine therapy in patients with ER-positive, HER2-negative advanced breast cancer. ⚠️ Imlunestrant is not FDA approved yet so it cannot be routinely used but hopefully will be a new option in the future! Love seeing all these advances to treat metastatic breast cancer. Let me know your questions! #breastcancer #sabcs24 #imlunestrant #metastaticbreastcancer #stageIVneedsmore
⭐️ Let’s talk about the EMBER-3 trial which was presented today and published in @nejm. Imlunestrant is a novel, next-generation, brain-penetrant (!!), oral selective estrogen receptor degrader (SERD) and pure estrogen receptor antagonist. It delivers continuous estrogen receptor inhibition even in ESR1 mutated breast cancer (where there is a mutation in the gene encoding the estrogen receptor alpha). 🔸In the EMBER-3 trial, patients with HR+/HER2- metastatic breast cancer that had developed a recurrence or progression during or after AI therapy (65% had also received. CDK 4/6 inhibitor). Patients received either standard endocrine monotherapy (330 patients) (fulvestrant or exemestane), imlunestrant alone (331 patients), or imlunestrant + abemaciclib (Verzenio, a CDK 4/6 inhibitor) (213 patients). 🔸Imlunestrant improved progression free survival (PFS) (time without progression or death) compared to standard endocrine therapy: 5.5 mo vs 3.8 months in patients with ESR1 mutations. There was no difference in patients who did not have ESR1 mutations. 🔸 Imlunestrant+abemaciclib vs imlunestrant alone improved PFS in all patients: 9.4 mo vs 5.5 months (43% reduction in risk of progression or death). The benefit was seen regardless of ESR1 mutation status. 🙄The common side effects of imlunestrant include: fatigue 😴, diarrhea 💩, nausea 🤢 and joint pain 🦴. (Side effects were increased when fulvestrant combined with abemaciclib). Preliminary analysis suggests that imlunestrant therapy involves ⬇️ risks of bradycardia (slow heart rate), high cholesterol, and visual 👀 disturbances than other new SERDs. 🚨 Bottom line: Imlunestrant, as monotherapy or in combination with abemaciclib, provides an oral targeted-therapy option after progression during endocrine therapy in patients with ER-positive, HER2-negative advanced breast cancer. ⚠️ Imlunestrant is not FDA approved yet so it cannot be routinely used but hopefully will be a new option in the future! Love seeing all these advances to treat metastatic breast cancer. Let me know your questions! #breastcancer #sabcs24 #imlunestrant #metastaticbreastcancer #stageIVneedsmore
#cintamonyet #videolucu #videokocak #lucungakak #bikinketawa
#cintamonyet #videolucu #videokocak #lucungakak #bikinketawa
ประธานฮั่ว 7#ซีรี่ย์จีน
ประธานฮั่ว 7#ซีรี่ย์จีน


#fyp #contenido #like #ondeado
#fyp #contenido #like #ondeado
Wait I wanna make a high protein cinnamon roll 👀 #proteindessert #proteinpowderreview
Wait I wanna make a high protein cinnamon roll 👀 #proteindessert #proteinpowderreview

About

Legal